A previous study demonstrated that the anti-hepatic steatosis effect of HQT in L02 hepatocytes inhibits SREBP-1 expression and increases CPT-1 and ACOX-1 expression via activation of the AMPK and PPAR-α pathways (Yin et al., 2014). The gene discussed is PPARA; the disease is fatty liver disease.